Skip to content

Study · Observational study · n = 4,426 · 2018

5 results

Real-world comparison of treatment patterns and effectiveness of albiglutide and liraglutide.

Buysman EK, Sikirica MV, Thayer SW, Bogart M, DuCharme MC, Joshi AV

Journal of comparative effectiveness research17 Aug 2017Cited by 4 (Europe PMC)

PMID28814107 (opens in a new tab)DOI10.2217/cer-2017-0032 (opens in a new tab)PepBankPUB-28814107
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyOther

    In adults with type 2 diabetes, adherence at 6 months was lower with liraglutide (0.64) than with albiglutide (0.69).

    In plain wordsIn adults with type 2 diabetes, people took liraglutide less consistently than albiglutide at 6 months.

    Peptide
    Liraglutide
    Outcome
    DecreaseMedication adherence at 6 months
    Study

    n = 4,426

    Comparator
    Albiglutide
    Outcome group
    Treatment adherence and retention · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    At 6 months, mean ± standard deviation adherence was 0.69 ± 0.29 versus 0.64 ± 0.29 (p < 0.001), and discontinuation was 33.2 versus 37.8% (p = 0.002) with albiglutide versus liraglutide, but these were not statistically or clinically different at 12 months.
    1 context sentence
    Summary · context
    Administrative claims data and glycated hemoglobin (HbA1c) results were analyzed from a sample of adult health plan members with Type 2 diabetes.
  2. 02HumanObservational studyOther

    In adults with type 2 diabetes, discontinuation at 6 months was higher with liraglutide (37.8%) than with albiglutide (33.2%).

    In plain wordsIn adults with type 2 diabetes, more people stopped liraglutide than albiglutide by 6 months.

    Peptide
    Liraglutide
    Outcome
    IncreaseDiscontinuation at 6 months
    Study

    n = 4,426

    Comparator
    Albiglutide
    Outcome group
    Treatment adherence and retention · Whole body
    Studied dose
    Dose not stated

    Measurements

    Discontinuation
    37.8%
    liraglutide at 6 months

    Source sentences

    Summary
    At 6 months, mean ± standard deviation adherence was 0.69 ± 0.29 versus 0.64 ± 0.29 (p < 0.001), and discontinuation was 33.2 versus 37.8% (p = 0.002) with albiglutide versus liraglutide, but these were not statistically or clinically different at 12 months.
    1 context sentence
    Summary · context
    Administrative claims data and glycated hemoglobin (HbA1c) results were analyzed from a sample of adult health plan members with Type 2 diabetes.
  3. 03HumanObservational studyOther

    In adults with type 2 diabetes, adherence at 12 months did not differ between liraglutide and albiglutide.

    In plain wordsIn adults with type 2 diabetes, liraglutide and albiglutide showed similar adherence at 12 months.

    Peptide
    Liraglutide
    Outcome
    No significant changeMedication adherence at 12 months
    Study

    n = 4,426

    Comparator
    Albiglutide
    Outcome group
    Treatment adherence and retention · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    but these were not statistically or clinically different at 12 months.
    1 context sentence
    Summary · context
    Administrative claims data and glycated hemoglobin (HbA1c) results were analyzed from a sample of adult health plan members with Type 2 diabetes.
  4. 04HumanObservational studyOther

    In adults with type 2 diabetes, discontinuation at 12 months did not differ between liraglutide and albiglutide.

    In plain wordsIn adults with type 2 diabetes, similar numbers stopped liraglutide and albiglutide by 12 months.

    Peptide
    Liraglutide
    Outcome
    No significant changeDiscontinuation at 12 months
    Study

    n = 4,426

    Comparator
    Albiglutide
    Outcome group
    Treatment adherence and retention · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    but these were not statistically or clinically different at 12 months.
    1 context sentence
    Summary · context
    Administrative claims data and glycated hemoglobin (HbA1c) results were analyzed from a sample of adult health plan members with Type 2 diabetes.
  5. 05HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, mean HbA1c fell by 1.0% from baseline with liraglutide, the same as with albiglutide.

    In plain wordsIn adults with type 2 diabetes, liraglutide lowered HbA1c by 1.0%, the same drop as albiglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change from baseline
    Study

    n = 488

    Comparator
    Albiglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    HbA1c change
    1%
    liraglutide

    Source sentences

    Summary
    Mean HbA1c change from baseline was -1.0% for both groups.
    1 context sentence
    Summary · context
    Patients were matched 1:1 in the albiglutide (n = 2213) and liraglutide (n = 2213) overall cohorts and in 244 patients with HbA1c results from each treatment group.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.